Skip to main content
SpringerLink
Log in

Moxonidine and Ramipril in Patients with Hypertension and Obstructive Pulmonary Disease

  • Clinical Use
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

Objectives: To investigate the tolerability and efficacy of moxonidine in the treatment of arterial hypertension in patients with obstructive pulmonary disease. The ACE inhibitor ramipril was used as a reference agent.

Patients and Methods: A group of 104 adult patients with arterial hypertension and respiratory disorders took part in a double-blind, randomised, parallel-group, single-centre study. During the eight-week treatment phase, patients received either moxonidine (0.2 or 0.4 mg/day) or the ACE inhibitor ramipril (2.5 or 5 mg/day).

Results: Small, nonsignificant changes in arterial oxygen partial pressure (PaO2) were observed during the treatment period with both moxonidine and ramipril. Forced expiratory volume in one second (FEV1) remained constant during treatment with moxonidine. A slight decrease in FEV1 with ramipril was not statistically significant (p > 0.1). The 24-hour blood pressure measurements showed that systolic and diastolic blood pressures were reduced with moxonidine (p = 0.018 and p = 0.009, respectively) and with ramipril (p < 0.001 for both measurements).

Conclusions: Moxonidine and ramipril exhibited comparable antihypertensive efficacy. Lung function was unchanged during treatment with moxonidine, suggesting that this new antihypertensive agent may be an appropriate choice of medication for patients with essential hypertension and concomitant obstructive pulmonary disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II
Table III
Table IV
Table V
Fig. 2
Fig. 3
Table VI

Similar content being viewed by others

References

  1. Kaplan NM. Hypertension in the population at large. In: Kaplan NM, editor. Clinical hypertension, Baltimore: Williams & Wilkens, 1994: 1–22

    Google Scholar 

  2. Mannino DM, Gagnon RC, Petty TL, et al. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988–1994. Arch Intern Med 2000; 160: 1683–9

    Article  PubMed  CAS  Google Scholar 

  3. Gulsvik A. Mortality in and prevalence of chronic obstructive pulmonary disease in different parts of Europe. Monaldi Arch Chest Dis 1999; 54: 160–2

    PubMed  CAS  Google Scholar 

  4. Prichard BNC. Clinical experience with moxonidine. Cardiovasc Drugs Ther 1994; 8Suppl. 1: 49–58

    Article  PubMed  Google Scholar 

  5. Ernsberger P, Damon TH, Graff LM, et al. Moxonidine, a centrally acting antihypertensive agent, is a selective ligand for I1-imidazoline sites. J Pharmacol Exp Ther 1993; 264: 172–82

    PubMed  CAS  Google Scholar 

  6. Ernsberger P, Haxhiu MA, Graff LM, et al. A novel mechanism of action for hypertension control: moxonidine as a selective I1-imidazoline agonist. Cardiovasc Drugs Ther 1994; 8Suppl. 1: 27–41

    Article  PubMed  Google Scholar 

  7. Haxhiu MA, Dreshaj I, Schafer SG, et al. Selective antihypertensive action of moxonidine is mediated mainly by I1-imidazoline receptors in the rostral ventrolateral medulla. J Cardiovasc Pharmacol 1994; 24Suppl. 1: 1–8

    Article  Google Scholar 

  8. Ernsberger P. The I1-imidazoline receptor agonist moxonidine: molecular, cellular and organismic actions. Rev Contemp Pharmacother 1998; 9: 441–62

    CAS  Google Scholar 

  9. McNeill RS. Effects of a beta-adrenergic-blocking agent, propranolol, on asthmatics. Lancet 1984; II: 1101–2

    Google Scholar 

  10. Geefhorst APM, van Herwaarden CLA. Comparative study of the ventilatory effects of three beta-selective blocking agents in asthmatic patients. Eur J Clin Pharmacol 1981; 20: 417–21

    Article  Google Scholar 

  11. Wilkens H, Wilkens JH, Hecht M, et al. Effect of moxonidine, an alpha-2-adrenergic agonist, on histamine-induced bronchial constriction and ventilatory occlusion responses to carbon dioxide in asthmatics. 3rd Cardiovascular Pharmacology International Symposium, 1989, Kyoto

  12. Jaeger B, Verboom C, Brunner H. The clinical efficacy of moxonidine in hypertension. Rev Contemp Pharmacother 1998; 9: 463–71

    Google Scholar 

  13. Frei M, Kuster L, Gardosch von Krosigk PP, et al. Moxonidine and hydrochlorothiazide in combination: a synergistic antihypertensive effect. J Cardiovasc Pharmacol 1994; 24Suppl. 1: 25–8

    Article  Google Scholar 

  14. Kraft K, Vetter H. Twenty-four-hour blood pressure profiles in patients with mild-to-moderate hypertension: moxonidine versus captopril. J Cardiovasc Pharmacol 1994; 24Suppl. 1: 29–33

    Article  Google Scholar 

  15. Ollivier JP, Christen MO. I1-imidazoline-receptor agonists in the treatment of hypertension: an appraisal of clinical experience. J Cardiovasc Pharmacol 1994; 24Suppl. 1: 39–48

    Article  Google Scholar 

  16. Prichard BNC, Simmons R, Rooks MJ, et al. A double-blind comparison of moxonidine and atenolol in the management of patients with mild to moderate hypertension. J Cardiovasc Pharmacol 1992; 20Suppl. 4: 45–9

    Article  Google Scholar 

  17. Wolf R. The treatment of hypertensive patients with a calcium antagonist or moxonidine: a comparison. J Cardiovasc Pharmacol 1992; 20Suppl. 4: 42–4

    Article  Google Scholar 

  18. Schachter M, Luszick J, Jaeger B, et al. Safety and tolerability of moxonidine in the treatment of hypertension. Drug Saf 1998; 19: 191–203

    Article  PubMed  CAS  Google Scholar 

  19. Sides GD, Leschinger MI, Walenta R, et al. The tolerability and adverse event profile of moxonidine. Rev Contemp Pharmacother 1998; 9: 491–98

    CAS  Google Scholar 

  20. Feuring M, Cassel W, Stawenow D, et al. Safety of moxonidine in patients with mild-to-moderate hypertension and chronic pulmonary disease [abstract]. Eur J Clin Pharmacol 1996; 50: 533

    Google Scholar 

Download references

Acknowledgements

Financial support for this study was provided by Solvay pharmaceuticals, Germany.

Author information

Authors and Affiliations

  1. Institute of Clinical Pharmacology, Faculty of Clinical Medicine Mannheim, University of Heidelberg, 68135, Mannheim, Germany

    Martin Feuring & Martin Wehling

  2. Clinic of Internal Medicine of the Philipps University, Marburg, Germany

    Werner Cassel, Ludger Grote, Thomas Penzel & Joerg Hermann Peter

  3. P.F.K. GmbH, Institute of Medical Research, Kaufbeuren, Germany

    Barbara Thun

Authors
  1. Martin Feuring
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Werner Cassel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Barbara Thun
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ludger Grote
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Martin Wehling
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Thomas Penzel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Joerg Hermann Peter
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin Feuring.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Feuring, M., Cassel, W., Thun, B. et al. Moxonidine and Ramipril in Patients with Hypertension and Obstructive Pulmonary Disease. Clin. Drug Investig. 20, 19–24 (2000). https://doi.org/10.2165/00044011-200020010-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-200020010-00003

Keywords

Search

Navigation